✦ LIBER ✦

Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes

✍ Scribed by B. Charbonnel; G. Schernthaner; P. Brunetti; D. R. Matthews; R. Urquhart; M. H. Tan; M. Hanefeld

Publisher: Springer
Year: 2005
Tongue: English
Weight: 244 KB
Volume: 48
Category: Article
ISSN: 0012-186X
DOI: 10.1007/s00125-005-1751-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Long-term therapy with addition of piogl

Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study

✍ D. R. Matthews; B. H. Charbonnel; M. Hanefeld; P. Brunetti; G. Schernthaner 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 122 KB 👁 2 views

Long-term effects on lipids and lipoprot

Long-term effects on lipids and lipoproteins of pioglitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulphonylurea in the treatment of type 2 diabetes

✍ D. J. Betteridge; B. Vergès 📂 Article 📅 2005 🏛 Springer 🌐 English ⚖ 135 KB

Efficacy and safety of the PPARγ partial

Efficacy and safety of the PPARγ partial agonist balaglitazone compared with pioglitazone and placebo: a phase III, randomized, parallel-group study in patients with type 2 diabetes on stable insulin therapy

✍ Kim Henriksen; Inger Byrjalsen; Per Qvist; Henning Beck-Nielsen; Gitte Hansen; B 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 357 KB 👁 1 views

## Abstract ## Background Treatment of patients with perioxisome proliferator‐activated receptor‐γ full agonists are associated with weight gain, heart failure, peripheral oedema, and bone loss. However, the safety of partial perioxisome proliferator‐activated receptor‐γ agonists has not been esta